{
    "Trade/Device Name(s)": [
        "Dextramer\u00ae CMV Kit"
    ],
    "Submitter Information": "Immudex ApS",
    "510(k) Number": "K153538",
    "Predicate Device Reference 510(k) Number(s)": [
        "K051122"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "GKZ"
    ],
    "Summary Letter Date": "February 22, 2017",
    "Summary Letter Received Date": "February 24, 2017",
    "Submission Date": "February 28, 2017",
    "Regulation Number(s)": [
        "21 CFR 864.5220"
    ],
    "Regulation Name(s)": [
        "Automated differential cell counter"
    ],
    "Analyte Class(es)": [
        "immunology",
        "hematology",
        "transplant"
    ],
    "Analyte(s)": [
        "Cytomegalovirus (CMV)-specific CD8+ T cells"
    ],
    "Specimen Type(s)": [
        "Whole blood"
    ],
    "Specimen Container(s)": [
        "Heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "FACSCanto II flow cytometer"
    ],
    "Method(s)/Technology(ies)": [
        "Flow cytometry",
        "MHC multimer staining"
    ],
    "Methodologies": [
        "Enumeration of antigen-specific T cells",
        "Semi-quantitative assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Immudex Dextramer CMV Kit, a semi-quantitative flow cytometry assay to enumerate CMV-specific CD8+ T cells in whole blood of adult stem cell transplant patients.",
    "Indications for Use Summary": "Intended for identification and enumeration of CMV-specific CD8+ T cells in Na Heparin whole blood by flow cytometry to assess CMV-specific immune status and risk of CMV reactivation in adult human stem cell transplant patients, in conjunction with other findings; not for measurement of CMV infection or disease and limited to specific HLA types.",
    "fda_folder": "Hematology"
}